A Placebo-controlled study of Maralixibat in Subjects with Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

IRB
CHLA-19-00365
MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) – MARCH-PFIC

To find out the effects of Maralixibat on the treatment of PFIC.

Study Details
Clinical Trials Government Identifier
NCT03905330
Keywords
maralixibat PFIC, Progressive Familial Intrahepatic Cholestasis
Eligibility
Children 1 to 18 years with diagnosis of PFIC with or without genetic testing
Does this study also recruit healthy volunteers?
No
Enrollment Status
Closed
Coordinator Contact
Carly Weaver
Contact Email
cweaver@chla.usc.edu